LeonaBio (LONA) Return on Capital Employed (2020 - 2026)
LeonaBio (LONA) reported Return on Capital Employed of 146.19% for Q1 2026, up 3506.0% year-over-year from 4.05% in Q1 2025, and up 80.57% on a QoQ basis from 752.56% in Q4 2025.
LeonaBio (LONA) has 7 years of Return on Capital Employed data on file, last reported at 146.19% in Q1 2026.
- Quarterly Return on Capital Employed rose 3506.0% year-over-year to 146.19% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 146.19% (up 3506.0% YoY) and the FY2025 annual result came in at 365.73%, down 26104.0% from the prior year.
- Return on Capital Employed climbed to 146.19% in Q1 2026 per LONA's latest filing, from 752.56% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.48% in Q1 2022 and bottomed at 752.56% in Q4 2025.
- The 5-year median for Return on Capital Employed is 101.76% (2024), against an average of 137.67%.
- The widest annual swing landed in 2025, when Return on Capital Employed sank 58263 bps; it then surged 3506 bps in 2026.
- Tracing LONA's Return on Capital Employed over 5 years: stood at 42.5% in 2022, then plunged by 106 bps to 87.35% in 2023, then plunged by 95 bps to 169.93% in 2024, then tumbled by 343 bps to 752.56% in 2025, then soared by 81 bps to 146.19% in 2026.
- Per Business Quant, the three latest LONA Return on Capital Employed figures stand at 146.19% (Q1 2026), 752.56% (Q4 2025), and 130.88% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | -146.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -146.19% |
| Dec 31, 2025 | -752.56% |
| Sep 30, 2025 | -130.88% |
| Jun 30, 2025 | -169.68% |
| Mar 31, 2025 | -181.26% |
| Dec 31, 2024 | -169.93% |
| Sep 30, 2024 | -161.06% |
| Jun 30, 2024 | -125.48% |
| Mar 31, 2024 | -101.76% |
| Dec 31, 2023 | -87.35% |
| Sep 30, 2023 | -77.13% |
| Jun 30, 2023 | -59.61% |
| Mar 31, 2023 | -49.00% |
| Dec 31, 2022 | -42.50% |
| Sep 30, 2022 | -32.94% |
| Jun 30, 2022 | -28.54% |
| Mar 31, 2022 | -24.48% |
| Dec 31, 2021 | -19.38% |
| Sep 30, 2021 | -15.78% |
| Jun 30, 2021 | -12.29% |
| Mar 31, 2021 | -9.22% |
| Dec 31, 2020 | -7.42% |